Editact Therapeutics has been selected as a top 5 finalist in the EQT Impact Challenge, 2025. The contest aims to find the leading pre-seed or early s…

Editact Therapeutics, a pioneering start-up in advanced genome editing technology, announces that its project has been selected as one of the first ba…

Editact Therapeutics is thrilled to announce that its core technology has been awarded the prestigious Gold Medal at the International Exhibition of I…